Product image of Granisetrón Normon (Granisetron) supplied by GNH India

Granisetrón Normon

Active Ingredient:
Granisetron
Origin:
EU

Granisetrón Normon (Granisetron)

Granisetrón Normon is a prescription‑only intravenous formulation of the active ingredient granisetron, a selective 5‑HT3 receptor antagonist used as an antiemetic. Marketed in the European Union, this product contains granisetron in a sterile solution for IV administration; the exact strength is not disclosed in the available data. It belongs to the therapeutic class of anti‑nausea agents and works by blocking serotonin receptors in the central and peripheral nervous system.

Manufacturer / TM Owner

Laboratorios Normon, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetrón Normon is indicated for the prevention and treatment of nausea and vomiting associated with specific medical procedures.

  • Chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
  • Post‑operative nausea and vomiting (PONV) following surgical procedures.
  • Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
  • Administration when rapid onset of antiemetic effect is required, such as before induction of anesthesia.
  • Situations where oral antiemetics are not feasible or tolerated.

Side Effects

The safety profile of Granisetrón Normon reflects the typical effects observed with 5‑HT3 receptor antagonists.

Common

  • Headache.
  • Constipation.
  • Diarrhea.
  • Transient dizziness.

Serious

  • Severe allergic reaction (anaphylaxis, rash, swelling).
  • Cardiac arrhythmia or QT prolongation.
  • Serotonin syndrome when combined with serotonergic agents.

Precautions & Warnings

When prescribing Granisetrón Normon, clinicians should consider several precautionary measures to ensure safe use.

  • Assess patient history for cardiac conduction abnormalities or prolonged QT interval.
  • Use caution in patients with hepatic impairment; dosage adjustment may be required.
  • Evaluate for hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Monitor for signs of severe constipation or bowel obstruction.
  • Consider pregnancy and lactation status; safety data are limited.
  • Review concomitant use of other serotonergic drugs.

Avoid Interactions

Granisetrón Normon may interact with other medications; awareness of these interactions helps prevent adverse events.

Avoid

  • Concurrent use with other 5‑HT3 antagonists (duplicate antiemetic effect).
  • Drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

  • Serotonergic agents such as SSRIs, SNRIs, tramadol, or MAO inhibitors (risk of serotonin syndrome).
  • Medications metabolized by CYP3A4 (e.g., certain macrolide antibiotics, antifungals) as granisetron is partially cleared hepatically.
  • Electrolyte disturbances (hypokalemia, hypomagnesemia) that may increase QT risk.

Frequently Asked Questions

Granisetrón Normon works by selectively antagonizing peripheral and central 5‑HT3 receptors, preventing serotonin‑mediated stimulation of the chemoreceptor trigger zone and gastrointestinal vagal afferents.

It is prescribed for adults undergoing chemotherapy with moderate to high emetogenic potential or for patients after surgery where postoperative nausea and vomiting are anticipated.

The product is supplied as a sterile intravenous solution that is administered by a healthcare professional under controlled conditions.

Safety data for use during pregnancy are limited; the product should be used only if the potential benefit justifies the potential risk to the fetus.

Common adverse effects include headache, constipation, diarrhea, and transient dizziness.

Serious reactions may include severe allergic responses such as anaphylaxis, cardiac arrhythmias or QT prolongation, and serotonin syndrome when combined with serotonergic drugs.

Patients with hepatic impairment should be monitored closely, and dose adjustments may be necessary based on clinical judgment.

Concurrent use of multiple 5‑HT3 antagonists should be avoided to prevent duplicate therapy and increased risk of side effects.

Drugs that also prolong the QT interval, such as certain antiarrhythmics, antipsychotics, and some antibiotics, should be avoided or used with caution.

The product should be stored according to the manufacturer’s instructions, typically in a cool, dry place protected from light, and used before the expiration date.

Co‑administration with serotonergic agents like SSRIs should be done with caution due to the potential for serotonin syndrome.

Monitoring may include assessment of cardiac rhythm, especially QT interval, evaluation for allergic reactions, and observation for severe constipation or bowel obstruction.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT